Table 2.
Baseline characteristic of the CovILD study cohort and the study participants stratified by COVID-19 severity
| Variablea | Entire cohort | Ambulatory CoV subset | Moderate CoV subset | Severe CoV subset | Significanceb | Effect sizeb |
|---|---|---|---|---|---|---|
| Sex |
Female: 41% (n = 44) Male: 59% (n = 64) |
Female: 67% (n = 18) Male: 33% (n = 9) |
Female: 35% (n = 19) Male: 65% (n = 36) |
Female: 27% (n = 7) Male: 73% (n = 19) |
p < 0.001 | V = 0.31 |
| Age, years |
56 [IQR: 49–68] Range 19–87 |
47 [IQR: 38–55] Range 19–70 |
62 [IQR: 53–72] Range 27–87 |
56 [IQR: 52–64] Range 44–79 |
p < 0.001 | η2 = 0.21 |
| BMI at CoV onset |
Normal: 39% (n = 42) Overweight: 43% (n = 46) Obesity: 19% (n = 20) |
Normal: 56% (n = 15) Overweight: 33% (n = 9) Obesity: 11% (n = 3) |
Normal: 29% (n = 16) Overweight: 51% (n = 28) Obesity: 20% (n = 11) |
Normal: 42% (n = 11) Overweight: 35% (n = 9) Obesity: 23% (n = 6) |
p < 0.001 | V = 0.17 |
| Comorbidity present | 75% (n = 81) | 41% (n = 11) | 85% (n = 47) | 88% (n = 23) | p < 0.001 | V = 0.46 |
| Cardiovascular disease | 40% (n = 43) | 7.4% (n = 2) | 47% (n = 26) | 58% (n = 15) | p < 0.001 | V = 0.39 |
| Arterial hypertension | 27% (n = 29) | 7.4% (n = 2) | 27% (n = 15) | 46% (n = 12) | p < 0.001 | V = 0.31 |
| Pulmonary disease | 19% (n = 20) | 11% (n = 3) | 22% (n = 12) | 19% (n = 5) | p = 0.031 | V = 0.11 |
| Metabolic disease | 42% (n = 45) | 19% (n = 5) | 49% (n = 27) | 50% (n = 13) | p < 0.001 | V = 0.27 |
| Diabetes II | 15% (n = 16) | 3.7% (n = 1) | 15% (n = 8) | 27% (n = 7) | p < 0.001 | V = 0.23 |
| Gastrointestinal disease | 13% (n = 14) | 0% (n = 0) | 20% (n = 11) | 12% (n = 3) | p < 0.001 | V = 0.24 |
| Malignancy | 9.3% (n = 10) | 3.7% (n = 1) | 15% (n = 8) | 3.8% (n = 1) | p < 0.001 | V = 0.19 |
| Immune deficiency | 5.6% (n = 6) | 0% (n = 0) | 3.6% (n = 2) | 15% (n = 4) | p < 0.001 | V = 0.25 |
Numeric variables are presented as medians with interquartile ranges (IQR) and ranges. Categorical variables are presented as percentages and counts within the complete observation set
aBMI at CoV onset: body mass index at COVID-19 onset, normal: BMI < 25 kg/m2, overweight: BMI 25–30 kg/m2, obesity: BMI > 30 kg/m2
bComparison of ambulatory, moderate and severe COVID-19 individuals. Categorical variables: χ2 test with Cramer V effect size statistic. Numeric variables: Kruskal–Wallis test with η2 effect size statistic. P values corrected form multiple testing with Benjamini–Hochberg method